LiViliti Receives FDA Clearance for Paptizer 360 CPAP Device

SARASOTA, Florida—LiViliti Health Products Corp., a provider of continuous positive airway pressure (CPAP) care solutions, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360. Classified as a Class II Respiratory Accessory Microbial Reduction Device, the Paptizer 360 provides a supplemental, at-home bacterial reduction process on compatible CPAP equipment.

“This clearance marks a significant milestone for LiViliti as we continue to provide users with scientifically validated tools for their respiratory health,” said Brian Sharpe, CEO of LiViliti Health Products Corp. “The Paptizer 360 offers a fast, effective and ozone-free way to supplement daily cleaning routines.”